CCL2 and neoplasm: Notably, in vivo targeting of the eEF2K/MCP-1 signaling axis with siRNA-nanotherapeutics inhibits tumor growth, induces apoptosis, and reduces the accumulation of pro-tumorigenic M2-TAMs in orthotopic mouse models of PDAC.